Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: December 15, 2023Press Announcements FDA News Release
  FDA Roundup: December 15, 2023

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  December 15, 2023
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, the FDA updated the breast implants web pages to share the latest information on:

	Risks and complications related to breast implants
		Reports of squamous cell carcinoma (SCC), various lymphomas other than Breast Implants Associated Anaplastic Large Cell Lymphoma( BIA-ALCL), and mesenchymal tumors, including sarcoma.
		Labeling for approved breast implants.
		Medical Device Reports posted between January 1, 2008, and June 30, 2023, for systemic symptoms in women with breast implants.
		Medical Device Reports from U.S and worldwide cases found in literature for breast implants associated with anaplastic large cell lymphoma (BIA-ALCL) and postmarket safety of breast implants.
	Today, the FDA issued draft guidance intended to help animal drug sponsors pursuing Priority Zoonotic Animal Drug (PZAD) designation for a new animal drug. PZADs are new animal drugs that have the potential to prevent or treat a zoonotic disease in animals, including a vector-borne disease, that has the potential to cause serious adverse health consequences for, or serious or life-threatening diseases in humans. This guidance is intended to expedite the development and review of these drugs. The FDA is accepting public comments on the draft guidance until February 16, 2024.
	On Thursday, the FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). The most common adverse reactions (≥25% incidence) in patients receiving belzutifan were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase. View full prescribing information for Welireg.
	On Thursday, the FDA announced that the Center for Devices and Radiological Health (CDRH) began participating in three new collaborative communities in the medical device ecosystem. These new collaborations focus on topics related to artificial intelligence, infection management, and diagnostic tests.
	On Thursday, the FDA announced the issuance of nine warning letters to manufacturers and distributors of unapproved antimicrobial drugs for nonfood minor animal species such aquarium fish and pet birds. These products are marketed over the counter without medical oversight, which can contribute to the development of antimicrobial resistance.
	On Thursday, the FDA updated the public health advisory for the investigation of Listeria monocytogenes linked to peaches, plums, and nectarines, to include a link to the updated recall announcement which now includes a list of retail locations that the FDA has reason to believe received the recalled peaches, plums & nectarines This list will be updated as additional information is collected by the FDA. More information is available in the public health advisory.
	On Wednesday, the FDA announced it will open the Voluntary Qualified Importer Program (VQIP) application portal for fiscal year (FY) 2025. VQIP is a voluntary fee-based program that provides importers, who achieve and maintain control over the safety and security of their supply chains, the benefits of expedited review and importation of human and animal foods into the United States.
	On Wednesday, the FDA approved the PulseSelect Pulse Field Ablation (PFA) system for cardiac electrophysiological mapping (stimulation and recording) and to treat atrial fibrillation (Afib) using electrical pulses to ablate cardiac tissue. According to the Centers for Disease Control and Prevention, it is estimated that 12.1 million people in the United States will have the condition in 2030. The PulseSelect PFA system has several components, including a generator and a loop catheter that ablate tissue with fast electrical pulses that form holes in the thin membrane around each cell (irreversible electroporation) instead of with thermal energy. In 2018, the FDA granted Breakthrough Devices designation to the PulseSelect PFA system because it represented a breakthrough technology that could provide more effective treatment for a life-threatening or irreversibly debilitating condition, among other criteria. Conventional thermal ablation for the treatment of Afib may lead to adverse events such as injury to the esophagus. Today’s approval brings to market an alternative treatment modality that may reduce such risks. The FDA granted approval, subject to certain post-approval study requirements, of the PulseSelect PFA system to Medtronic, Inc.
	On Wednesday, the FDA announced that the investigation of Salmonella linked to Onions is over and CDC announced that the outbreak has ended. CDC reports a total of 80 illnesses in 23 states. There has been a total of 18 hospitalizations and one death associated with this incident. The last illness onset was November 11, 2023. FDA’s investigation is complete. More information is available in the public health advisory.
	On Wednesday, the FDA approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. The most common adverse reactions (≥5%), including laboratory abnormalities, were otitis media, diarrhea, cough, sinusitis, pneumonia, upper respiratory tract infection, conjunctivitis, vomiting, pyrexia, allergic rhinitis, decreased neutrophils, increased ALT, increased AST, hearing loss, skin infection, and urinary tract infection.  This represents the first FDA approval of a therapy intended to reduce the risk of relapse in pediatric patients with HRNB. View full prescribing information for IWILFIN.
	On Tuesday, the FDA sent a safety alert advising restaurants and retailers not to serve or sell and consumers not to eat chopped clams likely harvested from a prohibited area  in Massachusetts and distributed by Red’s Best.
	On Tuesday, the FDA authorized marketing for Ankon Technologies’ NaviCam ProScan, software as a medical device. The device is based on artificial intelligence (AI) technology, designed for use with the NaviCam Small Bowel Capsule Endoscopy System. Patients with suspected small bowel bleeding swallow a disposable, single use camera pill, which takes pictures (images) of the small bowel as it travels through the digestive tract. A health care professional then reviews the images to identify any bleeding in the small bowel. NaviCam ProScan is indicated to aid in decreasing the time to review capsule endoscopy images. ProScan uses AI to analyze the images and presents the reader with any images that indicate bleeding. NaviCam ProScan is not intended to replace a thorough review of the video, nor is it intended to replace clinical decision making.Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      12/15/2023
               
               
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical Devices   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop